Novavax, Inc. (NVAX)
| Market Cap | 1.03B |
| Revenue (ttm) | 1.25B |
| Net Income (ttm) | 478.70M |
| Shares Out | 161.97M |
| EPS (ttm) | 2.97 |
| PE Ratio | 2.13 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,234,622 |
| Open | 6.05 |
| Previous Close | 5.98 |
| Day's Range | 6.04 - 6.45 |
| 52-Week Range | 4.43 - 23.86 |
| Beta | 3.20 |
| Analysts | Buy |
| Price Target | 17.50 (+176.03%) |
| Earnings Date | May 8, 2025 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $17.5, which is an increase of 176.03% from the latest price.
News
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven ...
COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.
Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Of...
Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
Novavax has seen its shares plummet since the pandemic because of weakening demand.
Novavax swings to profit on lower expenses related to COVID shots
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted i...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Novavax to Participate in BofA Securities 2025 Health Care Conference
GAITHERSBURG, Md. , May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.
Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will conti...
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
GAITHERSBURG, Md. , May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m.
Novavax Appoints Charles Newton to Board of Directors
GAITHERSBURG, Md. , April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director.
FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports
Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people fam...
FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say.
Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F. Kennedy Jr cast doubt on...
Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax, Inc. NAVX stock traded higher on Wednesday.
FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Novavax said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.
SHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
Preliminary data showed Novavax's non-mRNA JN.1 COVID-19 vaccine induced lower frequency and severity of short-term side effects and impact on daily life compared with Pfizer-BioNTech mRNA vaccine Ful...
Novavax shares tumble after U.S. health secretary raises concerns over COVID shot's efficacy
Vaccine maker Novavax's shares plunged over 22% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr. raised concerns about the company's COVID-19 vaccine in an interview with CB...
The FDA was moving to grant full approval for Novavax's Covid-19 vaccine. But it missed the April 1 deadline after the agency's vaccine chief was forced out.
The agency is sitting on a decision to grant full approval for Novavax's shot.
FDA misses deadline for decision on Novavax's COVID-19 vaccine, WSJ reports
The U.S. Food and Drug Administration have missed the deadline for making a key decision on Novavax's COVID-19 vaccine, the Wall Street Journal reported on Wednesday, citing people familiar with the m...
Vaccine stocks fall following FDA resignation
Dr. Kavita Patel joins 'Fast Money' to talk the impact of FDA and HHS changes on vaccines, public health policy, and more.
Vaccine stocks tumble: Moderna, Novavax, Pfizer fall after top FDA official resigns over RFK Jr. anti-vax views
Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration's (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec...
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump admin...
Vaccine stocks fall after key FDA official resigns in protest of RFK Jr.
Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks. Marks stepped down in protest of Health and Hum...
Biotech stocks tumble on reports FDA's top vaccine regulator to leave
Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S. Food and Drug Administration had resigned, fanning worries over slowe...